In recent years, there has been increasing talk of new obesity drugs on the market, and it is not hard to see why. Molecules such as semaglutide and tirzepatide have radically changed the way doctors and patients approach weight loss, shifting the focus from an approach based solely on diet and physical activity to more structured pharmacological strategies.
This scenario has generated a weight-loss drug boom, fuelled by concrete clinical results but also by ever-higher expectations. Patients are no longer just looking for weight reduction, but for an effective, sustainable, and potentially rapid solution capable of intervening in hunger, metabolism, and eating behaviour.
In this context, the success of GLP-1 agonist drugs represents one of the most significant changes of recent decades. However, behind the enthusiasm, new questions are emerging: how sustainable are these treatments? What risks do they entail? And what impact will they have on the healthcare system and health in the long term? This is precisely where the theme shifts from innovation to management.
The introduction of incretins has marked a concrete turning point in the treatment of obesity. Today, talking about weight-loss innovations almost always refers to this class of drugs, which are capable of acting on multiple levels: appetite, gastric emptying, and insulin response.
Clinical evidence shows results that are difficult to achieve with other approaches. Some treatments allow for weight reductions of up to 20% or more, with benefits that are not limited to the scales but also involve metabolic and cardiovascular parameters.1
This has led to a rapid spread of new weight-loss drugs, transforming them into one of the most widely used tools in obesity management. These are no longer niche solutions but therapies that are entering daily clinical practice and, increasingly, public debate.
The phenomenon can be described as a true weight-loss drug explosion, with exponential growth in prescriptions over the last few years.2
This change does not just concern the numbers, but also how people perceive weight loss. GLP-1 drugs intervene directly in the mechanisms of hunger, reducing so-called “food noise” and making it easier to maintain a calorie deficit.
As a consequence, the impact of weight-loss drugs on daily life is also changing. The relationship with food, portion management, and the perception of hunger are profoundly altered, creating a completely different experience compared to traditional journeys.
At the same time, this success opens up a more complex issue: when a therapy becomes so effective, the risk is to consider it a self-sufficient solution without questioning what happens during and, above all, after the treatment. It is precisely here that the first critical issues begin to emerge.
The expansion of incretin-based treatments has brought an inevitable question: GLP-1 agonist costs and long-term sustainability. Today, for many patients, access to these therapies is limited by a monthly cost that makes treatment difficult to sustain without healthcare support.
This scenario has a direct impact not only on individuals but on the entire system. The increasing adoption of GLP-1 drugs has already generated a significant rise in healthcare spending, with figures in some contexts exceeding hundreds of millions of dollars per year3.
The central point is not just the cost of the drug, but its chronic nature. Obesity is not a temporary condition, and this means many patients require prolonged, if not continuous, treatment. Consequently, the economic model shifts from a “cycle-based” therapy to management over time, with profound implications for sustainability.
In addition, other factors amplify the impact of GLP-1 at a systemic level:
Globally, the potential patient pool is enormous. It is estimated that over a quarter of the adult population could be eligible for these treatments.4 This means that if access were to broaden, the economic impact would be even more significant.
At the same time, structural criticalities emerge:
Added to this is a strategic element: the possible evolution of the market. The expiration of patents and the arrival of biosimilars could drastically reduce costs in the coming years, changing the balance of access and distribution.
Meanwhile, the significant growth in the use of weight-loss drugs poses a concrete question: can the healthcare system sustain such an effective yet widespread therapy over time? The answer depends on the ability to integrate these drugs into broader care models, preventing them from becoming an isolated solution.
And just as the focus shifts from cost to value, another level of complexity emerges: that of risks and side effects.
The effectiveness of incretins has contributed to reinforcing the perception of a direct solution to the weight problem. However, talking about the risks of GLP-1 weight-loss drugs means bringing the topic back to a more realistic clinical level, where benefits and limitations coexist.
These drugs are indicated in specific contexts, such as clinical obesity or Type 2 diabetes, and always within a structured medical pathway. Problems emerge when they are used outside of these conditions, often with high expectations and without adequate monitoring.
In these cases, the risks of drugs for losing weight become more evident: not so much due to their pharmacological nature, but because of the context in which they are placed. Obesity is a chronic and complex pathology, and treating it as a temporary problem can lead to unstable or incomplete results.
One of the most relevant aspects concerns side effects, which represent one of the main causes of treatment discontinuation.
The most frequent are gastrointestinal in nature:
These symptoms can appear as early as the first few weeks and, in some cases, compromise adherence to treatment.
Alongside these common effects, less obvious but more significant long-term criticalities emerge. These include:
In this scenario, the issue is not determining whether the drugs are safe or not, but understanding how to reduce GLP-1 risks in a concrete way. The answer does not lie in stopping the therapy, but in integrating it into a broader pathway that includes nutrition, physical activity, and clinical support.
Observing these effects reveals a key point: the value of GLP-1 is not measured solely by weight loss, but by their overall impact on health.
To truly understand the role of these therapies, it is necessary to go beyond simple weight loss and analyse the health impact of GLP-1. GLP-1 agonist drugs do not only act on hunger; they influence various biological systems, with effects extending to metabolism, the cardiovascular system, and glycemic regulation.
This explains why their use initially spread for the treatment of diabetes, before extending to obesity management.
The impact is therefore broader than that of a classic weight-loss drug. However, this very breadth necessitates a more careful approach, because every benefit exists within a complex balance.
One of the most significant effects concerns metabolic control. The link between GLP-1 and diabetes is direct: these molecules improve insulin secretion, reduce blood sugar peaks, and contribute to more stable glycemic management.
Alongside this, important cardiovascular benefits are emerging. Clinical data show that some drugs in this class can reduce the risk of major cardiovascular events, such as heart attack and stroke, by up to 20%, even in non-diabetic patients.
This reinforces the role of anti-obesity drugs and cardiovascular health as one of the primary areas of evolution in metabolic therapy.
Other observed effects include:
These results explain why the use of GLP-1 is considered one of the most relevant innovations in managing metabolic diseases.
However, the picture is not linear. The same mechanisms that bring benefits can generate side effects or imbalances if not managed correctly. How do these drugs compare to other available weight-loss solutions?
In the current landscape, understanding the differences in GLP-1 weight-loss drugs compared to other approaches is fundamental to correctly interpreting their role. Unlike traditional solutions, these therapies act directly on the physiological mechanisms of hunger and satiety, modifying eating behaviour at its root.
This distinguishes them from restrictive diets, supplements, or standardised protocols, which often only intervene in the calorie balance without significantly influencing the biological signals that regulate appetite.
However, this greater effectiveness brings higher complexity. GLP-1 are not neutral tools: they act on a delicate system, and for this reason, they require careful management. The issue of health risks of glucagon for weight loss fits right here, highlighting how pharmacological intervention must always be evaluated in relation to the patient’s profile.
Furthermore, while the drugs produce evident results in the short term, their long-term effectiveness depends on the ability to maintain the changes achieved. Without adequate support, the risk is weight loss that is effective but unstable.
Alternatives exist and, in many cases, represent a necessary complement rather than a replacement. Diet, physical activity, behavioural interventions, and the use of the right food supplements remain the foundation of any journey, even when pharmacological therapy is introduced.
In recent years, a more integrated approach is also developing, which includes nutritional and functional support. In this context, the role of supplements in maintaining good health becomes central, especially for managing nutritional deficiencies, supporting muscle mass, and improving the tolerability of the therapy.
This integration is particularly relevant because GLP-1 drugs reduce food intake, increasing the risk of nutritional imbalances. Without adequate support, the weight-loss journey can become less sustainable over time.
In light of these considerations, GLP-1 do not replace other strategies but fit into a broader model. The real change does not concern the individual tool, but the way it is used.
And it is precisely here that the key point emerges: the future of obesity treatment is not tied to a single solution, but to the ability to integrate medication, nutrition, and behaviour into a coherent and sustainable pathway.
References